UroGen Pharma (URGN) Q2 2026 earnings review
ZUSDURI Hyper-Growth Puts Profitability in Sight
UroGen's Q2 results validate the blockbuster potential of ZUSDURI. Total revenue skyrocketed 199% YoY to $72.5M, driven by $50.4M in ZUSDURI sales (+73% QoQ). The permanent J-code implementation from January has completely unlocked demand, with repeat prescribers climbing to 45% of the base. This massive revenue beat translated to tremendous operating leverage: Net Loss reversed sharply to just $14.4M, compared to $49.9M a year ago. While JELMYTO sales disappointed by shrinking 9% YoY, the sheer scale of the ZUSDURI ramp makes the legacy product's stagnation a secondary issue.
🐂 Bull Case
With 1,444 activated sites and a 73% sequential revenue jump, the drug is establishing itself rapidly. The transition to community practice settings is working, and the 45% repeat prescriber rate signals high clinical conviction.
The new U.S. patent allowance extending protection for ZUSDURI and next-gen UGN-103 into July 2044 removes long-term generic overhang and cements terminal value.
🐻 Bear Case
Legacy drug JELMYTO contracted 9% YoY to $22.0M. The company maintains its $97-$101M full-year target, which now looks mathematically challenging without a stark H2 reacceleration.
Management hiked FY26 operating expense guidance to $260M-$270M (from $240M-$250M). While framed as 'investing in success,' this delays the exact cash-flow breakeven point.
⚖️ Verdict: 🟢
Bullish. The ZUSDURI launch is tracking flawlessly. The product is scaling so fast that it will likely fund its own commercial footprint and pipeline development by early 2027, minimizing dilution risk.
Key Themes
ZUSDURI Adoption Metrics are Accelerating
The core thesis for UroGen hinges on ZUSDURI replacing repeated TURBT surgeries. The Q2 numbers are staggering: $50.4M in sales, 1,444 activated sites, and 452 unique prescribers. Crucially, the quality of adoption is deepening. Repeat prescribers hit 204 (45% of the total), up from 103 in Q1. The removal of reimbursement friction (via the permanent J-code) has permanently altered the product's trajectory.
JELMYTO's Reversing Trajectory Creates Guidance Risk
JELMYTO revenue fell to $22.0M from $24.2M a year ago (-9%). Despite this, management reaffirmed FY26 guidance of $97-$101M. Having generated just $43.7M in H1, JELMYTO needs to produce roughly $55M in H2 to hit the midpoint. This implies an aggressive reacceleration in a mature product, suggesting a high likelihood of a stealth guidance miss later this year.
Intellectual Property Horizon Greatly Expanded
A massive de-risking event occurred with the Notice of Allowance for a new U.S. patent covering treatment methods without TURBT. Expected to provide protection into July 2044, this completely changes the terminal value math for both ZUSDURI and its next-gen successor, UGN-103. It gives UroGen nearly two decades of monopoly pricing power in the recurrent LG-IR-NMIBC market.
Expense Spend is Accelerating Faster than Expected
Management bumped full-year operating expense guidance to $260M-$270M (an increase of $20M). While SG&A ($48.4M in Q2) is justifiably high to support the ZUSDURI land grab, this increased cash burn requires monitoring. Q2's net loss was $14.4M, meaning profitability is close, but 'accelerating investments' will push the true breakeven quarter slightly further into the future.
Next-Gen Pipeline and RTGel Technology Validation
UroGen is aggressively cannibalizing its own success to stay ahead. UGN-103, utilizing a streamlined manufacturing process for the proprietary RTGel platform, is on track for a Q3 2026 NDA submission. Furthermore, the FDA accepted the IND for UGN-501 (an investigational oncolytic virus for high-grade disease), with Phase 1 starting in Q4 2026. This validates the RTGel delivery platform beyond simple mitomycin chemoablation.
JELMYTO Generic Settlement De-risks Medium Term
UroGen settled patent litigation with Teva, granting them a license to sell a generic version of JELMYTO starting September 15, 2030. While it caps the product's lifespan, it provides a stable 4-year runway without legal overhang, allowing management to focus entirely on the ZUSDURI/UGN-103 transition.
Other KPIs
Reversing trend. This is a dramatic improvement from the $49.9M loss in Q2 2025 and $23.6M loss in Q1 2026. ZUSDURI's 90%+ gross margins are falling straight to the bottom line, radically outstripping the concurrent increases in SG&A. This is textbook operating leverage.
Down from $120.4M at the end of 2025. Given the shrinking quarterly net loss ($14.4M) and the explosive ZUSDURI revenue growth, this cash buffer is more than sufficient to reach sustainable free cash flow without requiring dilutive equity raises.
Decelerating YoY (down from $18.9M in Q2 2025). The drop is due to accounting: last year, ZUSDURI manufacturing was billed as R&D prior to FDA approval. Underlying clinical spend remains healthy as they prep the UGN-103 NDA.
Guidance
Stable (Unchanged from prior quarters). Management stuck to this target despite printing just $22.0M in Q2 (-9% YoY). To achieve the $99M midpoint, H2 revenues must average ~$27.5M per quarter. This requires a significant reacceleration that contradicts current trajectory.
Accelerating. Raised from the prior $240M-$250M range. The company explicitly cited the need to accelerate investment behind ZUSDURI's strong launch (peer-to-peer education, patient awareness) and to front-load start-up costs for the UGN-103 high-grade trial.
Key Questions
JELMYTO H2 Math
JELMYTO revenue contracted 9% YoY this quarter, yet you maintained full-year guidance which implies a massive step-up in H2. What specific market dynamics or pricing actions give you confidence in hitting that $97M floor?
ZUSDURI Peak Capacity
With 452 unique prescribers out of an 8,500 target universe, we are at ~5% penetration, yet revenue is already at a $200M run rate. Is the initial cohort treating a disproportionately large backlog of patients, and should we expect revenue per prescriber to normalize lower?
Transitioning the Market to UGN-103
With the UGN-103 NDA on track for Q3, how are you planning the commercial pivot in 2027/2028 to avoid cannibalizing ZUSDURI's momentum or confusing the recently-converted community prescriber base?